Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults

Robert Vassallo, Jay H Ryu, Darrell R. Schroeder, Paul A. Decker, Andrew Harold Limper

Research output: Contribution to journalArticle

297 Citations (Scopus)

Abstract

Background: Pulmonary Langerhans'-cell histiocytosis is an uncommon interstitial lung disease in adults. It has an unpredictable course and may be associated with an increased susceptibility to the development of malignant neoplasms. Methods: We reviewed the records of 102 adults with histopathologically confirmed pulmonary Langerhans'-cell histiocytosis to ascertain their vital status and whether cancer had been diagnosed. The health status of surviving patients was quantified with the use of the 36-Item Short-Form General Health Survey. Factors potentially associated with survival after the diagnosis of pulmonary Langerhans'-cell histiocytosis were analyzed with the Cox proportional-hazards model. Results: The median follow-up period was 4 years (range, 0 to 23). There were 33 deaths, 15 of which were attributable to respiratory failure. Six hematologic cancers were diagnosed. The overall median survival was 12.5 years, which was significantly shorter than that expected for persons of the same sex and calendar year of birth (P<0.001). In a univariate analysis, variables predictive of shorter survival included an older age (P=0.003), a lower forced expiratory volume in one second (FEV1) (P=0.004), a higher residual volume (P=0.007), a lower ratio of FEV1 to forced vital capacity (P=0.03), and a reduced carbon monoxide diffusing capacity (P=0.001). Conclusions: The survival of adults with pulmonary Langerhans'-cell histiocytosis is shorter than that in the general population, and respiratory failure accounts for a substantial proportion of deaths among such patients.

Original languageEnglish (US)
Pages (from-to)484-490
Number of pages7
JournalNew England Journal of Medicine
Volume346
Issue number7
DOIs
StatePublished - Feb 14 2002

Fingerprint

Langerhans Cell Histiocytosis
Lung
Survival
Respiratory Insufficiency
Neoplasms
Residual Volume
Interstitial Lung Diseases
Vital Capacity
Forced Expiratory Volume
Carbon Monoxide
Health Surveys
Proportional Hazards Models
Health Status
Parturition
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. / Vassallo, Robert; Ryu, Jay H; Schroeder, Darrell R.; Decker, Paul A.; Limper, Andrew Harold.

In: New England Journal of Medicine, Vol. 346, No. 7, 14.02.2002, p. 484-490.

Research output: Contribution to journalArticle

@article{0822acb3a56841f3a0bb95325d105ae6,
title = "Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults",
abstract = "Background: Pulmonary Langerhans'-cell histiocytosis is an uncommon interstitial lung disease in adults. It has an unpredictable course and may be associated with an increased susceptibility to the development of malignant neoplasms. Methods: We reviewed the records of 102 adults with histopathologically confirmed pulmonary Langerhans'-cell histiocytosis to ascertain their vital status and whether cancer had been diagnosed. The health status of surviving patients was quantified with the use of the 36-Item Short-Form General Health Survey. Factors potentially associated with survival after the diagnosis of pulmonary Langerhans'-cell histiocytosis were analyzed with the Cox proportional-hazards model. Results: The median follow-up period was 4 years (range, 0 to 23). There were 33 deaths, 15 of which were attributable to respiratory failure. Six hematologic cancers were diagnosed. The overall median survival was 12.5 years, which was significantly shorter than that expected for persons of the same sex and calendar year of birth (P<0.001). In a univariate analysis, variables predictive of shorter survival included an older age (P=0.003), a lower forced expiratory volume in one second (FEV1) (P=0.004), a higher residual volume (P=0.007), a lower ratio of FEV1 to forced vital capacity (P=0.03), and a reduced carbon monoxide diffusing capacity (P=0.001). Conclusions: The survival of adults with pulmonary Langerhans'-cell histiocytosis is shorter than that in the general population, and respiratory failure accounts for a substantial proportion of deaths among such patients.",
author = "Robert Vassallo and Ryu, {Jay H} and Schroeder, {Darrell R.} and Decker, {Paul A.} and Limper, {Andrew Harold}",
year = "2002",
month = "2",
day = "14",
doi = "10.1056/NEJMoa012087",
language = "English (US)",
volume = "346",
pages = "484--490",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "7",

}

TY - JOUR

T1 - Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults

AU - Vassallo, Robert

AU - Ryu, Jay H

AU - Schroeder, Darrell R.

AU - Decker, Paul A.

AU - Limper, Andrew Harold

PY - 2002/2/14

Y1 - 2002/2/14

N2 - Background: Pulmonary Langerhans'-cell histiocytosis is an uncommon interstitial lung disease in adults. It has an unpredictable course and may be associated with an increased susceptibility to the development of malignant neoplasms. Methods: We reviewed the records of 102 adults with histopathologically confirmed pulmonary Langerhans'-cell histiocytosis to ascertain their vital status and whether cancer had been diagnosed. The health status of surviving patients was quantified with the use of the 36-Item Short-Form General Health Survey. Factors potentially associated with survival after the diagnosis of pulmonary Langerhans'-cell histiocytosis were analyzed with the Cox proportional-hazards model. Results: The median follow-up period was 4 years (range, 0 to 23). There were 33 deaths, 15 of which were attributable to respiratory failure. Six hematologic cancers were diagnosed. The overall median survival was 12.5 years, which was significantly shorter than that expected for persons of the same sex and calendar year of birth (P<0.001). In a univariate analysis, variables predictive of shorter survival included an older age (P=0.003), a lower forced expiratory volume in one second (FEV1) (P=0.004), a higher residual volume (P=0.007), a lower ratio of FEV1 to forced vital capacity (P=0.03), and a reduced carbon monoxide diffusing capacity (P=0.001). Conclusions: The survival of adults with pulmonary Langerhans'-cell histiocytosis is shorter than that in the general population, and respiratory failure accounts for a substantial proportion of deaths among such patients.

AB - Background: Pulmonary Langerhans'-cell histiocytosis is an uncommon interstitial lung disease in adults. It has an unpredictable course and may be associated with an increased susceptibility to the development of malignant neoplasms. Methods: We reviewed the records of 102 adults with histopathologically confirmed pulmonary Langerhans'-cell histiocytosis to ascertain their vital status and whether cancer had been diagnosed. The health status of surviving patients was quantified with the use of the 36-Item Short-Form General Health Survey. Factors potentially associated with survival after the diagnosis of pulmonary Langerhans'-cell histiocytosis were analyzed with the Cox proportional-hazards model. Results: The median follow-up period was 4 years (range, 0 to 23). There were 33 deaths, 15 of which were attributable to respiratory failure. Six hematologic cancers were diagnosed. The overall median survival was 12.5 years, which was significantly shorter than that expected for persons of the same sex and calendar year of birth (P<0.001). In a univariate analysis, variables predictive of shorter survival included an older age (P=0.003), a lower forced expiratory volume in one second (FEV1) (P=0.004), a higher residual volume (P=0.007), a lower ratio of FEV1 to forced vital capacity (P=0.03), and a reduced carbon monoxide diffusing capacity (P=0.001). Conclusions: The survival of adults with pulmonary Langerhans'-cell histiocytosis is shorter than that in the general population, and respiratory failure accounts for a substantial proportion of deaths among such patients.

UR - http://www.scopus.com/inward/record.url?scp=0037075269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037075269&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa012087

DO - 10.1056/NEJMoa012087

M3 - Article

C2 - 11844849

AN - SCOPUS:0037075269

VL - 346

SP - 484

EP - 490

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 7

ER -